Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Health Research Projects

University of Ottawa

$67,989.00

Novel biomaterials and photocages with anti-viral activity for transplantation

FY 2009-10

Summary
RATIONALE AND BACKGROUND: Herpes simplex virus (HSV) infections in the cornea has an incidence of up to 500,000 cases each year in the US alone. Once infected, the virus becomes latent and remains within the cornea and nerves. When reactivated (by a range of triggers including certains foods, sunlight, surgery), the patient will have recurrences of the disease. The disease leads to ulceration of the corneal surface to deeper ullcerations, loss of nerve sensitivity leading to scarring and corneal blindness or even corneal perforation. Patients are treated with systemic anti-viral drugs but corneal transplantation is the treatment of choice to restore vision, even though the prognosis is extremely poor - 22% success over 5 years. The poor prognosis is due to the HSV latency and reactivation. An effective treatment is therefore needed. OBJECTIVE: Our objective therefore is to develop an effective treatment, using tissue engineering and photochemistry approaches. PROPOSED RESEARCH: We will combine our previous success in developing artificial corneas that have allowed corneal cell and nerve regeneration when implanted into pigs with new ways to delivery anti-viral drugs such as acyclovir. Novel photocages will be developed for precise, controlled release of acyclovir, and incorporated into corneal implants to release the drug during surgery to prevent HSV reactivation.We will also be testing the efficacy of anti-viral peptides, e.g. LL-37, in combating primary HSV infection and/or preventing viral reactivation. EXPECTED SIGNIFICANCE Our results could become a means by which drugs can be delivered to the eye (not just the cornea) and released bio-photonically. This would allow for high risk corneal transplants and transplants to the retina and other internal parts of the eye where drugs or growth factors need to be delivered and activated over time, without the use of invasive techniques like injection.
Program
Collaborative Health Research Projects
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
337436-2007
Name nom
Griffith, May
Department département
Cellular and Molecular Medicine
Organization id
28
Institution établissement
University of Ottawa
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2009
Competition year année de concours
2007
Award amount
67989
Program id
CHRPJ
Program nane en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Partie
3
Nb partie
3
Application title
Novel biomaterials and photocages with anti-viral activity for transplantation
Keyword
NA
Application summary
RATIONALE AND BACKGROUND: Herpes simplex virus (HSV) infections in the cornea has an incidence of up to 500,000 cases each year in the US alone. Once infected, the virus becomes latent and remains within the cornea and nerves. When reactivated (by a range of triggers including certains foods, sunlight, surgery), the patient will have recurrences of the disease. The disease leads to ulceration of the corneal surface to deeper ullcerations, loss of nerve sensitivity leading to scarring and corneal blindness or even corneal perforation. Patients are treated with systemic anti-viral drugs but corneal transplantation is the treatment of choice to restore vision, even though the prognosis is extremely poor - 22% success over 5 years. The poor prognosis is due to the HSV latency and reactivation. An effective treatment is therefore needed. OBJECTIVE: Our objective therefore is to develop an effective treatment, using tissue engineering and photochemistry approaches. PROPOSED RESEARCH: We will combine our previous success in developing artificial corneas that have allowed corneal cell and nerve regeneration when implanted into pigs with new ways to delivery anti-viral drugs such as acyclovir. Novel photocages will be developed for precise, controlled release of acyclovir, and incorporated into corneal implants to release the drug during surgery to prevent HSV reactivation.We will also be testing the efficacy of anti-viral peptides, e.g. LL-37, in combating primary HSV infection and/or preventing viral reactivation. EXPECTED SIGNIFICANCE Our results could become a means by which drugs can be delivered to the eye (not just the cornea) and released bio-photonically. This would allow for high risk corneal transplants and transplants to the retina and other internal parts of the eye where drugs or growth factors need to be delivered and activated over time, without the use of invasive techniques like injection.
University of Ottawa - $67,989 Grant (2009-10) | Canada Spends